Dr Lynn McCallum

Dr Lynn McCallum

Associate Professor of Haematology (Education)

School of Biomedical & Healthcare Sciences


Associate Professor in Haematology (Education)
Programme Lead Healthcare Sciences
Healthcare Sciences Workplace Training Co-ordinator


PhD University of Edinburgh
BSc (Hons) Queen's University Belfast
PGCAP Plymouth University 2012

Professional membership

American Society for Hematology
British Society for Haematology
International CCN Society
European Association for Cancer Research
Irish Association for Cancer Research
Fellow of the Higher Education Academy

Research interests

Investigation of CCN matricellular proteins in normal and malignant haematopoesis and solid tumour metastasis to bone. CCN proteins modulate stem cell signalling pathways including that of transforming growth factor beta, bone morphogenic protein, Notch and Wnt-beta-catenin. Abberations in CCN expression have been associated with a number of haematological malignancies including leukaemia and also in prostate cancer. CCN overexpression and knockdown systems have been created to identify the associated signalling pathways involved in tumourigenesis, advanced and resistant disease using gene array profiling. Identification of novel targeting strategies directed toward CCN associated stem cell signalling will allow development of novel therapeutics to more effectively target cancer.

Grants & contracts

Research and Innovation, Plymouth University R&I (2012, £37,250). Seedcorn investment to investigate ‘Targeting Prostate Cancer Progression’.

British Society for Haematology (2010, £6900). Start-up grant ‘Profiling CCN expression in Haematological malignancy’


Key publications are highlighted

Zaidi A, Dresman S, Charoltte B, Rule S & McCallum LMR 2018 'Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma' Journal of Cell Communication and Signaling Author Site Publisher Site , DOI PEARL
Suresh S, McCallum L, Crawford LJ, Lu WH, Sharpe DJ & Irvine AE 2013 'The matricellular protein CCN3 regulates NOTCH1 signalling in chronic myeloid leukaemia' The Journal of Pathology 231, (3) 378-387 , DOI
Burt C, Roddari J, Mindos T, Furtado M, Rule S & McCallum L 2013 'CCN1 modulates cell growth in aggressive mantle cell lymphoma' BRITISH JOURNAL OF HAEMATOLOGY 161, 44-44 Author Site
Yakkundi A, McCallum L, O'Kane A, Dyer H, Worthington J, McKeen HD, McClements L, Elliott C, McCarthy HO & Hirst DG 2013 'The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway' PLoS One 8, (2) Author Site , DOI
McCallum L, Lu W, Price S, Lazar N, Perbal B & Irvine AE 2011 'CCN3 suppresses mitogenic signalling and reinstates growth control mechanisms in Chronic Myeloid Leukaemia' Journal of Cell Communication and Signaling 6, (1) 27-35 , DOI
Suresh S, McCallum L, Lu W, Lazar N, Perbal B & Irvine AE 2011 'MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML' Journal of Cell Communication and Signaling 5, (3) 183-191 , DOI
Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L & Dyer H 2011 'FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism' Clin Cancer Res 17, (5) 1044-1056 Author Site , DOI
McCallum L, Lu W, Price S, Lazar N, Perbal B & Irvine AE 2009 'CCN3: a key growth regulator in Chronic Myeloid Leukaemia' Journal of Cell Communication and Signaling 3, (2) 115-124 , DOI
Lu W, McCallum L & Irvine AE 2009 'A rapid and sensitive method for measuring cell adhesion' Journal of Cell Communication and Signaling 3, (2) 147-149 , DOI
McCallum L & Irvine AE 2009 'CCN3 – A key regulator of the hematopoietic compartment' Blood Reviews 23, (2) 79-85 , DOI
Crawford LJ, Windrum P, Magill L, Melo JV, McCallum L, McMullin MF, Ovaa H, Walker B & Irvine AE 2009 'Proteasome proteolytic profile is linked to Bcr-Abl expression' Experimental Hematology 37, (3) 357-366 , DOI
McCallum L 2006 'A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation' Blood 108, (5) 1716-1723 , DOI
McCallum L & Irvine AE 2010 'CCN3: A novel growth factor in leukaemia' CCN Proteins in Health and Disease: An Overview of the Fifth International Workshop on the CCN Family of Genes 213-221 , DOI
Conference Papers
Zaidi A, Mindos T, Hutchinson C, Rule S & McCallum L 2016 'Dysregulation of CCN1 expression in conjunction with increased expression of p21(CIP1) and p27(KIP1) implicated in mantle cell lymphoma progression' 79-79
McCallum L, Lu W, Price S, Suresh S, Lazar N, Perbal B & Irvine S 2011 'CCN3 counteracts malignant features in chronic myeloid leukaemia' 14-14
Lu W, McCallum LMR, Price S, Planque N, Perbal B, Whettont AD & Irvine AE 2007 'CCN3 reduces the clonogenic potential of BCR-ABL plus cells' 26-26
Mccallum LMR, Lu W, Price S, Planque N, Perbal B, Pierce A, Whetton AD & Irvine AE 2006 'CCN3 expression reduces the clonogenic potential and growth of BCR-ABL plus cells' 13-14
McCallum LMR, Lu W, Price S, Planque N, Perbal B, Pierce A, Whetton A & Irvine AE 2005 'BCR-ABL decreases the expression of CCN3 leading to increased clonogenic potential and cell growth' 354A-354A


International CCN Society: http://ccnsociety.com/index.html

British Society for Haematology: http://www.b-s-h.org.uk/

Society for Endocrinology: http://www.endocrinology.org